[
  {
    "text": "1.1.62 \"Dispute' has the meaning ascribed to such term in Section 15.10.",
    "bbox": [
      248,
      95,
      866,
      110
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.63 \"Effective Date' has the meaning ascribed to such term in the Preamble..",
    "bbox": [
      248,
      132,
      914,
      146
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.64 \"EMA\" means the European Medicines Agency and any successor agency thereto in the EU having",
    "bbox": [
      246,
      167,
      1000,
      183
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "substantially the same function..",
    "bbox": [
      114,
      188,
      370,
      201
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.65 \"EU\" means the European Union or any successor union of European states thereto having a substantially",
    "bbox": [
      247,
      222,
      1000,
      237
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "similar function.",
    "bbox": [
      112,
      242,
      241,
      256
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.66 \"European Clinical Trial Countries\" means [***].",
    "bbox": [
      247,
      275,
      722,
      293
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.67 \"Excluded Licensing Transaction\"' means (a) a license or sublicense granted to an academic collaborator,",
    "bbox": [
      247,
      313,
      1000,
      328
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "service provider, contract research organization, contract manufacturer or similar Third Party that does not grant to such Third",
    "bbox": [
      111,
      333,
      1000,
      348
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Party any right to Commercialize the Product (other than, in the case of a CMO, the right to commercially manufacture PB2452 or",
    "bbox": [
      111,
      352,
      1000,
      367
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the Product on behalf of PB or its Affiliates, without any other right to Commercialize the Product), or (b) a license or sublicense",
    "bbox": [
      113,
      373,
      1000,
      385
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "not involving a grant of rights to the Product (by way of example and not of limitation, a license or sublicense to develop and",
    "bbox": [
      110,
      390,
      1000,
      405
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "commercialize any product based on PB's proprietary ELP technology, including PB1046 and PB1023).",
    "bbox": [
      111,
      409,
      996,
      424
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.68 \"Exclusive Period\"' means, subject to the earlier termination of the AZ License, (a) in the case of the",
    "bbox": [
      248,
      445,
      1000,
      458
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "conduct of human clinical trials with respect to a Competing Product, the period beginning on the Effective Date and ending on",
    "bbox": [
      111,
      465,
      1000,
      479
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "November 21, 2022, and (b) in the case of the sale or offer for sale of a Competing Product, the period beginning on the Effective",
    "bbox": [
      111,
      483,
      1000,
      498
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Date and ending on November 21, 2024.",
    "bbox": [
      112,
      503,
      463,
      516
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.69 \"Exercise Price'' has the meaning set forth in Section 8.1..",
    "bbox": [
      250,
      538,
      788,
      550
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.70 \"Executive Officers\"' means the executive officers of each of PB and SFJ identified on Exhibit E",
    "bbox": [
      249,
      574,
      1000,
      586
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.71 \"Existing Licenses\" means: (a) the License, Development and Commercialization Agreement dated March",
    "bbox": [
      248,
      609,
      1000,
      623
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "28, 2019, between PB and ImmunoForge Co., Ltd., including the ancillary agreements between such parties entered into in",
    "bbox": [
      112,
      629,
      1000,
      644
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "connection therewith; and (b) the License Agreement dated April 13, 2018, between PB and [***], as amended.",
    "bbox": [
      112,
      648,
      1000,
      662
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.72 *Existing PB Intellectual Property\"' has the meaning ascribed to such term in Section 11.1.1.1.",
    "bbox": [
      247,
      683,
      1000,
      697
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.73 \"Exploit\"' has the meaning ascribed to such term in the AZ License..",
    "bbox": [
      247,
      719,
      871,
      733
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1.74 *FDA\" means the US Food and Drug Administration and any successor agency thereto in the US having.",
    "bbox": [
      247,
      755,
      1000,
      770
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "substantially the same function..",
    "bbox": [
      114,
      776,
      370,
      788
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: PHASEBIO PHARMACEUTICALS INC, 10-K, 3/30/2020",
    "bbox": [
      133,
      1000,
      621,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]